Clinical Trials Browser

Enrolling by invitation × INDUSTRY × 90 days × Clear all

Neoplasms

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

430 enrolled

Advanced Malignancies

NCT07474051 2026-03-16

PERSIST

Enrolling by invitation

178 enrolled

GenitourinaryLymphoidOther hematologic neoplasm

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT06435312 2026-03-13

ziMyG+

Phase 3 Enrolling by invitation

8 enrolled

Myasthenia Gravis

NCT05332054 2026-03-12

LTFS

Enrolling by invitation

150 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

15 enrolled

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06540144 2026-02-27

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3 Enrolling by invitation

12 enrolled

Myasthenia Gravis

NCT05041309 2026-02-25

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitation

1,000 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT07158450 2026-02-25

NOECHO

Enrolling by invitation

50 enrolled

Heart Failure, Cardiotoxicity

NCT05303532 2026-02-23

ROSY-D

Phase 3 Enrolling by invitation

214 enrolled

Tumor-Agnostic

Neoplasms

NCT07116668 2026-02-18

SAFE-3CV

Phase NA Enrolling by invitation

108 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07417774 2026-02-18

RESTORE LB

Enrolling by invitation

40 enrolled

CNS

Glioblastoma

NCT06701201 2026-02-10

A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Enrolling by invitation

60 enrolled

Tumor-Agnostic

Neoplasms

NCT05374590 2026-02-02

ADAPT Jr +

Phase 2/3 Enrolling by invitation

12 enrolled

Myasthenia Gravis

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Phase 2 Enrolling by invitation

60 enrolled

Breast

TNBC

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Phase 3 Enrolling by invitation

250 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT06848088 2026-01-12

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Phase 2 Enrolling by invitation

48 enrolled

Dermatologic

Melanoma

NCT07316361 2026-01-07

GYNORYLAQ™

Phase EARLY_PHASE1 Enrolling by invitation

40 enrolled

Gynecologic

Endometrial Neoplasms

NCT04770571 2025-12-22

Posterior Cervical Fixation Study

Enrolling by invitation

150 enrolled

Klippel-Feil Syndrome, Radiculopathy, Thoracic Injuries, Trauma, Nervous System, Intervertebral Disc Degeneration

Clinical Trials

Development and Application of Patient-Derived Models of Cancer

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

PERSIST

ziMyG+

LTFS

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

NOECHO

ROSY-D

SAFE-3CV

RESTORE LB

A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

ADAPT Jr +

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

GYNORYLAQ™

Posterior Cervical Fixation Study